PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
PBYI on Nasdaq
Shares outstanding
49,633,071
Price per share
$5.95
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
34,367,867
Holdings value
$182,467,133
% of all portfolios
0%
Share change
+1,569,433
Value change
+$11,618,134
Average buys %
+0%
Average sells %
-0%
Number of holders
131
Price from insider filings
$5.88
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 8% +19% $11,465,551 +$1,922,381 3,940,052 +20% Anders Hove 31 Dec 2024
BlackRock, Inc. 5.6% $8,088,205 2,779,452 BlackRock, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.9% $5,511,907 1,894,126 Millennium Management LLC 31 Dec 2024
As of 30 Sep 2025, PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 131 institutional shareholders filing 13F forms. They hold 34,367,867 shares of 49,633,071 outstanding shares (69%) .

Top 25 institutional shareholders own 59% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
ACORN CAPITAL ADVISORS, LLC 8.3% 4,131,299 0% 11% $21,937,198
VANGUARD GROUP INC 7.4% 3,691,720 -0.4% 0% $19,603,033
BlackRock, Inc. 7.2% 3,577,877 -6.7% 0% $18,998,527
RENAISSANCE TECHNOLOGIES LLC 4.3% 2,151,213 +15% 0.02% $11,422,941
ACADIAN ASSET MANAGEMENT LLC 4.1% 2,053,305 +2.2% 0.02% $10,900,000
AMERICAN CENTURY COMPANIES INC 3% 1,483,188 +10% 0% $7,875,728
DIMENSIONAL FUND ADVISORS LP 2.6% 1,271,878 +11% 0% $6,751,930
GEODE CAPITAL MANAGEMENT, LLC 2% 983,522 +1.2% 0% $5,223,376
Russell Investments Group, Ltd. 1.9% 964,693 +4823365% 0.01% $5,122,519
Connor, Clark & Lunn Investment Management Ltd. 1.9% 943,472 +4.8% 0.02% $5,009,836
KENNEDY CAPITAL MANAGEMENT LLC 1.7% 867,630 -12% 0.1% $4,607,115
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 1.7% 828,221 +89% 0.03% $4,397,854
STATE STREET CORP 1.5% 748,658 +1.9% 0% $3,975,374
LSV ASSET MANAGEMENT 1.1% 559,921 +4.5% 0.01% $2,973,000
MARSHALL WACE, LLP 1.1% 557,548 +659% 0% $2,960,578
NORTHERN TRUST CORP 1.1% 526,736 +74% 0% $2,796,968
D. E. Shaw & Co., Inc. 1% 498,598 -22% 0% $2,647,555
RITHOLTZ WEALTH MANAGEMENT 0.95% 470,767 +139% 0.05% $2,499,773
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.94% 464,734 +2.9% 0% $2,467,738
GLOBEFLEX CAPITAL L P 0.91% 452,606 0% 0.37% $2,403,338
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.87% 433,561 +114% 0.05% $2,302,209
MORGAN STANLEY 0.76% 378,082 +17% 0% $2,007,615
UBS Group AG 0.76% 376,091 +37% 0% $1,997,043
Bank of New York Mellon Corp 0.72% 355,368 +3.3% 0% $1,887,005
SEI INVESTMENTS CO 0.7% 347,234 0% 0% $1,843,818

Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 10,409 $61,021 -$327,711 $5.95 4
2025 Q3 34,367,867 $182,467,133 +$11,618,134 $5.31 131
2025 Q2 32,782,327 $112,437,236 +$8,596,769 $3.43 121
2025 Q1 30,413,709 $90,021,037 +$2,952,606 $2.96 116
2024 Q4 29,394,627 $89,649,603 -$7,799,597 $3.05 111
2024 Q3 29,741,414 $75,860,252 -$5,783,394 $2.55 101
2024 Q2 30,964,332 $100,942,626 -$1,236,684 $3.26 98
2024 Q1 29,681,761 $157,343,204 +$15,794,537 $5.30 95
2023 Q4 57,200 $247,676 +$140,768 $4.33 1
2023 Q3 25,704,166 $67,598,924 -$2,428,875 $2.63 67
2023 Q2 26,576,438 $93,807,644 -$4,382,378 $3.53 67
2023 Q1 27,855,345 $86,065,002 -$528,043 $3.09 77
2022 Q4 27,479,113 $116,245,277 -$150,269 $4.23 84
2022 Q3 27,626,220 $65,467,451 -$1,680,707 $2.37 70
2022 Q2 27,597,810 $78,591,611 -$4,196,470 $2.85 74
2022 Q1 29,418,987 $84,673,643 -$204,643 $2.88 93
2021 Q4 30,174,656 $91,838,926 -$38,933,125 $3.04 94
2021 Q3 31,660,563 $222,489,183 -$28,802,542 $7.01 112
2021 Q2 34,054,533 $312,611,355 -$20,287,153 $9.18 116
2021 Q1 36,491,769 $354,663,814 +$11,746,965 $9.72 115
2020 Q4 32,059,891 $329,182,750 -$10,207,569 $10.26 118
2020 Q3 38,628,508 $389,739,466 +$12,671,903 $10.09 125
2020 Q2 32,128,867 $335,015,486 -$7,020,082 $10.43 121
2020 Q1 31,700,382 $267,348,388 +$39,210,336 $8.44 116
2019 Q4 31,074,561 $271,860,276 -$65,234,225 $8.75 127
2019 Q3 33,378,445 $359,419,047 +$12,539,026 $10.77 134
2019 Q2 31,766,131 $403,725,355 -$100,224,441 $12.71 128
2019 Q1 33,231,984 $1,289,111,060 +$6,936,347 $38.79 152
2018 Q4 34,920,997 $710,703,852 -$233,138,894 $20.35 133
2018 Q3 35,649,697 $1,634,461,087 +$1,144,533 $45.85 154
2018 Q2 35,470,341 $2,097,700,039 +$48,079,567 $59.15 167
2018 Q1 35,573,906 $2,419,781,006 -$81,263,808 $68.05 166
2017 Q4 36,156,451 $3,573,581,170 -$112,206,126 $98.85 192
2017 Q3 36,680,997 $4,391,693,256 +$169,751,693 $119.75 169
2017 Q2 35,525,549 $3,104,620,640 +$54,058,353 $87.40 152
2017 Q1 37,881,582 $1,409,361,790 +$189,597,584 $37.20 134
2016 Q4 34,931,458 $1,072,395,439 +$72,899,297 $30.70 127
2016 Q3 29,992,904 $2,010,275,475 +$5,534,182 $67.05 145
2016 Q2 31,637,934 $942,563,404 +$45,435,440 $29.79 105
2016 Q1 30,316,213 $890,078,817 -$117,526,991 $29.37 111
2015 Q4 32,166,774 $2,521,713,949 +$178,666,040 $78.40 130
2015 Q3 30,149,797 $2,271,709,092 -$28,151,083 $75.36 157
2015 Q2 30,146,471 $3,519,028,040 -$43,624,585 $116.75 194
2015 Q1 29,117,499 $6,872,560,525 +$477,847,712 $236.11 196
2014 Q4 27,136,421 $5,138,007,488 +$67,839,953 $189.27 182
2014 Q3 26,680,747 $6,365,417,896 +$471,007,610 $238.57 185
2014 Q2 25,369,132 $1,674,142,490 -$31,576,653 $66.00 131
2014 Q1 25,055,944 $2,609,326,453 +$105,834,812 $104.14 129